<DOC>
	<DOCNO>NCT02741570</DOCNO>
	<brief_summary>The main purpose study compare nivolumab ipilimumab Extreme study regimen first line treatment patient recurrent metastatic squamous cell head neck cancer</brief_summary>
	<brief_title>Study Nivolumab Combination With Ipilimumab Compared Standard Care ( Extreme Study Regimen ) First Line Treatment Patients With Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histologically confirm metastatic recurrent squamous cell carcinoma head neck ( oral cavity , oropharynx , hypopharynx &amp; larynx ) amenable curative therapy . No prior systemic cancer therapy recurrent metastatic disease ( except chemotherapy part multimodal treatment complete 6 month prior enrolment ) . Measurable disease detect image exam ( CT MRI ) . Have tumor tissue PD L1 expression testing , oropharyngeal cancer result test HPV p16 status . Metastatic recurrent carcinoma nasopharynx , squamous cell carcinoma unknown primary , squamous cell carcinoma originate skin salivary gland non squamous histology ( eg . mucosal melanoma ) . No prior treatment anti PD1 , anti PD L1 , anti CTLA 4 antibody antibody drug target T cell costimulation checkpoint pathway , cetuximab EGFR inhibitor treatment set . Patients certain disease active autoimmune disease , type I diabetes , hypothyroidism need hormone replacement , active infection , psychiatric disorder . Inadequate hematologic , renal hepatic function . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>